Avoro Capital Advisors LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Avoro Capital Advisors LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 115,751 shares of the company’s stock, valued at approximately $4,085,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in shares of Dyne Therapeutics during the first quarter valued at $140,666,000. Janus Henderson Group PLC grew its stake in Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after acquiring an additional 2,663,910 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $15,758,000. Price T Rowe Associates Inc. MD lifted its position in shares of Dyne Therapeutics by 8,284.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Activity

In related news, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO John Cox purchased 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,705 shares of company stock worth $437,701. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Trading Up 0.5 %

DYN opened at $36.59 on Monday. The stock’s 50 day simple moving average is $41.07 and its 200-day simple moving average is $33.66. The stock has a market cap of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. Equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Piper Sandler raised their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Morgan Stanley upped their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Finally, Guggenheim upped their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.